Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Description

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

Conditions

Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis

Talk to us

Study Overview

On this page

Study Details

Study overview

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Condition
Sickle Cell Disease
Intervention / Treatment

-

Contacts and Locations

Sacramento

UC Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
  • * Ability to provide written informed consent
  • * Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
  • * Negative urine pregnancy test for anyone of childbearing potential at study entry
  • * Pregnant women
  • * Adults unable to consent
  • * Individuals who are not yet adults (infants, children, teenagers)
  • * Prisoners
  • * Hospitalizations (for any cause) within 2 weeks of study entry

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Davis,

Oyebimpe O Adesina, MD, MS, PRINCIPAL_INVESTIGATOR, UC Davis School of Medicine

Study Record Dates

2026-06